GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Abattis Bioceuticals Corp (OTCPK:ATTBF) » Definitions » Net Income

Abattis Bioceuticals (Abattis Bioceuticals) Net Income : $-2.28 Mil (TTM As of Sep. 2019)


View and export this data going back to . Start your Free Trial

What is Abattis Bioceuticals Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Abattis Bioceuticals's Net Income for the three months ended in Sep. 2019 was $-0.69 Mil. Its Net Income for the trailing twelve months (TTM) ended in Sep. 2019 was $-2.28 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Abattis Bioceuticals's Earnings per Share (Diluted) for the three months ended in Sep. 2019 was $-0.00.


Abattis Bioceuticals Net Income Historical Data

The historical data trend for Abattis Bioceuticals's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abattis Bioceuticals Net Income Chart

Abattis Bioceuticals Annual Data
Trend Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.37 -1.78 -6.22 -59.85 -2.30

Abattis Bioceuticals Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -41.58 -0.94 -0.11 -0.55 -0.69

Abattis Bioceuticals Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Abattis Bioceuticals's Net Income for the fiscal year that ended in Sep. 2019 is calculated as

Net Income(A: Sep. 2019 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-2.312+0+0+0.015
=-2.30

Abattis Bioceuticals's Net Income for the quarter that ended in Sep. 2019 is calculated as

Net Income(Q: Sep. 2019 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-0.703+0+0+0.018
=-0.69

Net Income for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abattis Bioceuticals  (OTCPK:ATTBF) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Abattis Bioceuticals's Earnings per Share (Diluted) (EPS) for the quarter that ended in Sep. 2019 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Abattis Bioceuticals Net Income Related Terms

Thank you for viewing the detailed overview of Abattis Bioceuticals's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Abattis Bioceuticals (Abattis Bioceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1200 - 625 Howe Street, Vancouver, BC, CAN, V6C 2M6
Abattis Bioceuticals Corp is a Canadian life science and biotechnology company focuses on aggregating, integrating and investing in agricultural technologies and biotechnology services for the legal cannabis industry. It is primarily engaged in producing, licensing and marketing proprietary ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The company is also engaged in growing, extraction, testing, propagation and online distribution.

Abattis Bioceuticals (Abattis Bioceuticals) Headlines

From GuruFocus

Comfort Launch by Vergence Naturals Exceeds Expectations

By Marketwired Marketwired 12-11-2018

Abattis Bioceuticals Celebrates Legalization

By Marketwired Marketwired 10-18-2018

Abattis Bioceuticals Acquires Proprietary Genetic Strain Bank

By Marketwired Marketwired 11-23-2018

Abattis Removed From BCSC Temporary Order

By Marketwired Marketwired 01-17-2019

Abattis Announces Share Buy Back Program

By Marketwired Marketwired 08-07-2018

Abattis Announces Acquisition of Fertilizer Company NutriVida

By Marketwired Marketwired 12-08-2018

Abattis Bioceuticals Announces Release of New Line of Vaporizers

By Marketwired Marketwired 05-22-2018